Cat allergy immunotherapy(Circassia Group Plc)(Cat allergy immunotherapy(Circassia Group Plc))

概要

基本信息

药物类型

治疗性疫苗

别名

Cat allergen vaccine、Cat allergy immunotherapy、Cat-PAD

+ [3]

靶点-

作用机制

免疫调节剂

治疗领域

免疫系统疾病感染眼部疾病+ [2]

在研适应症-

非在研适应症

哮喘猫过敏（疾病）结膜炎+ [3]

原研机构

Niox Group Plc

在研机构-

非在研机构

Circassia Ltd.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

22

项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的临床试验

ISRCTN17973296

/ Completed早期临床1期

An open label, safety and allergenicity Phase 0 study of a new hypoallergenic plant-derived cat dander vaccine in adult cat allergic subjects

开始日期2023-09-14

申办/合作机构-

NCT02795273

/ Withdrawn临床2/3期

A Combined Phase 2b/3, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects With Grass Pollen-Induced Allergic Rhinitis, With or Without Conjunctivitis

The purpose of this study is to evaluate the safety of Grass-SPIRE compared with placebo and to evaluate the treatment effect of Grass-SPIRE on symptoms and use of rescue medication during the grass pollen season

开始日期2016-05-01

申办/合作机构

Circassia Ltd.

NCT02478060

/ Completed临床2期

A Double-Blind, Randomised, Placebo-Controlled, Escalating, Multiple Dose Study in to Assess the Safety, Tolerability and Pharmacodynamic Effects of Birch-SPIRE

The purpose of this study is to evaluate the safety and tolerability of multiple administrations of Birch-SPIRE. To make a preliminary assessment on pharmacodynamic parameters and clinical outcomes.

开始日期2015-07-01

申办/合作机构

Circassia Ltd.

[+2]

100 项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的临床结果

登录后查看更多信息

100 项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的转化医学

登录后查看更多信息

100 项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的专利（医药）

登录后查看更多信息

44

项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的文献（医药）

2024-03-11·ACS Biomaterials Science & Engineering

Self-Assembling Allergen Vaccine Platform Raises Therapeutic Allergen-Specific IgG Responses without Induction of Systemic Allergic Responses

Article

作者: Collier, Joel H. ; Cossette, Benjamin J. ; Issah, Luqman A. ; Shetty, Shamitha

Allergen immunotherapies are often successful at desensitizing allergic patients but can require life-long dosing and suffer from frequent adverse events including instances of systemic anaphylaxis, leading to poor patient compliance and high cost. Allergen vaccines, in turn, can generate more durable immunological allergen desensitization with far fewer doses. However, like immunotherapies, allergen vaccines are often highly reactogenic in allergic patients, hampering their use in therapeutic settings. In this work, we utilize a peptide-based self-assembling nanofiber platform to design allergen vaccines against allergen B-cell epitopes that do not elicit systemic anaphylaxis when administered subcutaneously to allergic mice. We show that, in contrast to protein vaccines, nanofiber vaccines prevent leakage of allergen material into the vascular compartment, a feature that likely underpins their reduced systemic reactogenicity. Further, we show that our allergen vaccine platform elicits therapeutic IgG antibody responses capable of desensitizing allergic mice to allergen-induced Type I hypersensitivity reactions. Finally, we have demonstrated a proof-of-concept for the therapeutic potential of nanofiber-based peanut allergen vaccines directed against peanut allergen-derived epitopes.

2023-03-01·ERJ Open Research

Adding a biologic to allergen immunotherapy increases treatment efficacy

Article

作者: Bożek, Andrzej ; Fischer, Andreas ; Canonica, Giorgio Walter ; Bogacz-Piaseczynska, Agnieszka

BackgroundThe application of allergen immunotherapy (AIT) in combination with biological agents has been found to increase both the safety and efficacy of the desensitisation procedure in patients with food and insect venom allergy. The aim of our study was to compare the effectiveness of AIT in patients with house dust mite (HDM)-driven asthma treated with and without omalizumab.Materials and methodsThe study was a placebo-controlled, three-armed, randomised, parallel-group, multicentre trial that included 52 patients with HDM-driven asthma. Only patients with monosensitisation to HDM were included. The study compared three patterns of therapy: omalizumab alone, HDM subcutaneous immunotherapy (SCIT-HDM)+ omalizumab, and SCIT alone. The main outcomes were evaluate the Asthma Control Questionnaire (ACQ) score, number of asthma exacerbations and reduction in the daily dose of inhaled steroids during 12 months of observation.ResultsAll variants of therapy led to significantly improved ACQ scores and reduction of asthma exacerbations in all study groups after 12 months of treatment. A statistically significant reduction in the daily doses of inhaled corticosteroids in the group with omalizumab alone (650±150 µgversus500±50 µg for p=0.003) or SCIT-HDM+omalizumab (550±250 µgversus375±75 µg for p=0.001) was observed, favouring the latter group.ConclusionThe efficacy of AIT for HDM-driven asthma is significantly increased by the combination of allergen vaccine with omalizumab.

2022-11-06·Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

[Expert consensus on diagnosis, treatment and prevention of allergic diseases (Part Ⅱ)].

Article

本文是共识的第二部分即过敏性疾病的治疗。原则是“防治结合、四位一体”：环境控制可避免或减少过敏原，是首选；过敏原疫苗脱敏治疗是对因治疗，已经被认为是一线治疗方法；靶向药物阻断过敏或抗过敏药物控制症状是目前常用的对症治疗方法，需要参照慢病管理方式用药；健康教育可改变患者的错误认知，提高患者主动性和依从性，改变行为方式，提高疗效。.

100 项与 Cat allergy immunotherapy(Circassia Group Plc) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
猫过敏（疾病）	临床3期	-	Circassia Ltd.	2014-02-01
鼻结膜炎	临床3期	波兰	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	美国	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	德国	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	比利时	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	斯洛伐克	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	俄罗斯	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	加拿大	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	捷克	Circassia Ltd.	2012-10-01
鼻结膜炎	临床3期	匈牙利	Circassia Ltd.	2012-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02040844 (CTgov)	临床3期	猫过敏（疾病）	430	placebo (Cat-PAD Treatment 1 (1 Course))	製餘壓獵窪鑰窪鏇淵選(鹹餘選網簾願艱選繭鏇) = 襯壓窪構憲鹽蓋繭憲糧構鹹餘網願網鑰襯鹽膚 (觸襯醖獵遞觸齋憲簾製, 製顧鹹鏇廠製範遞鏇淵 ~ 構夢選選製艱齋鹹鹹餘) 更多	-	2018-05-14
NCT02040844 (CTgov)	临床3期	猫过敏（疾病）	430	Cat-PAD (Cat-PAD Treatment (2 Courses))	製餘壓獵窪鑰窪鏇淵選(鹹餘選網簾願艱選繭鏇) = 製鏇壓壓膚網獵範製鏇構鹹餘網願網鑰襯鹽膚 (觸襯醖獵遞觸齋憲簾製, 夢顧選廠鹽膚蓋範膚網 ~ 願觸繭積獵糧膚鹽範構) 更多	-	2018-05-14
NCT01620762 (CTgov)	临床3期	鼻结膜炎	1,408	Placebo	醖簾積鏇製廠遞選顧壓(蓋糧觸選壓鏇構積願齋) = 構繭鹹壓製夢膚繭壓鑰衊構獵淵鑰鏇艱觸夢築 (範積糧願餘製醖廠襯鹽, 願醖顧醖遞醖蓋製鹽製 ~ 願築壓簾鑰顧壓鏇鏇糧) 更多	-	2018-05-14
ASCO2004	临床1/2期	多发性骨髓瘤	15	PAD combination	鏇選選積遞鏇鏇齋鹹夢(醖鹹遞餘範餘淵窪窪繭) = 齋窪積淵網淵鬱艱製遞簾窪積襯築衊遞憲餘鹹 (淵獵醖鬱夢糧淵壓繭襯 ) 更多	-	2004-07-15